|
|
|
|
Why Do Cancer Patients Suffer Twice ? 1. The Disease Itself & 2. The Treatment Of The Disease
A study was conducted by Dr.Forsythe on 225 patients for three years with varying Stage IV cancers. All patients utilized Poly-MVA and showed up to a 60% positive response rate with many continuing to survive years after the study. FOR IMMEDIATE...
|
|
|
New Animal Model for Evaluating Antiviral Agents Against the SARS Virus Indicates Potential Effect of Ampligen
PHILADELPHIA, Feb.8, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the 'Company') reported a recent study, published in the December 20th issue of Virology (2009) by a consortium of researchers at Utah State University and the...
|
|
|
Poly Medicure plans Rs 40 cr expansion in medical devices segment
_ Poly Medicure plans Rs 40 cr expansion in medical devices segment.
|
|
|
Cosmetic Use of Poly-l-Lactic Acid: A Retrospective Study of 130 Patients
_ Cosmetic Use of Poly-l-Lactic Acid: A Retrospective Study of 130 Patients.
|
|
|
Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That the FDA Seattle District Accepts Ampligen(R) Manufacturing Response
(GlobeNewswire via COMTEX) ----Hemispherx Biopharma, Inc.(NYSE Amex:HEB) (the "Company"), announced that the Company, via its manufacturing subcontractor, received a favorable response from the Food and Drug Administration ("FDA") Seattle District Office (...
|
|
|
Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That the FDA Seattle District Accepts Ampligen(R) Manufacturing Response
(GlobeNewswire via COMTEX) ----Hemispherx Biopharma, Inc.(NYSE Amex:HEB) (the "Company"), announced that the Company, via its manufacturing subcontractor, received a favorable response from the Food and Drug Administration ("FDA") Seattle District Office (...
|
|
|
Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That the FDA Seattle District Accepts Amp
PHILADELPHIA, Feb.2, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the Company), announced that the Company, via its manufacturing subcontractor, received a favorable response from the Food and Drug Administration (FDA) Seattle...
|
|
|
Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That the FDA Seattle District Accepts Ampligen(R) Manufacturing Response
PHILADELPHIA, Feb.2, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the ?Company?), announced that the Company, via its manufacturing subcontractor, received a favorable response from the Food and Drug Administration (?FDA?) Seattle...
|
|
|
Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That the FDA Seattle District Accepts Ampligen(R) Manufacturing Response
PHILADELPHIA, Feb.2, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the ?Company?), announced that the Company, via its manufacturing subcontractor, received a favorable response from the Food and Drug Administration (?FDA?) Seattle...
|
|
|
Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That the FDA Seattle District Accepts Ampligen(R) Manufacturing Response
Hemispherx Biopharma, Inc.(NYSE Amex:HEB) (the "Company"), announced that the Company, via its manufacturing subcontractor, received a favorable response from the Food and Drug Administration ("FDA") Seattle District Office ("DO") related to the latest...
|
|
|
Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That the FDA Seattle District Accepts Ampligen(R) Manufacturing Response
PHILADELPHIA, Feb.2, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex: HEB) (the "Company"), announced that the Company, via its manufacturing subcontractor, received a favorable response from the Food and Drug Administration ("FDA") Seattle...
|
|
|
Hemispherx Biopharma Receives Favorable Notice Via Its
PHILADELPHIA, Feb.2, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the 'Company'), announced that the Company, via its manufacturing subcontractor, received a favorable response from the Food and Drug Administration ('FDA') Seattle...
|
|
|
Gene Therapy: New gene therapy findings from University Hospital described
Today's Medical & Research News Gene Therapy New gene therapy findings from University Hospital described February 1st, 2010 Printer-Friendly Version City:Granada Country:Spain Adenosine Angiogenesis Biotechnology Drugs Enzymes Gene Therapy Genetics...
|
|
|
Inhibition of Poly(ADP)-Ribose Polymerase as a Therapeutic Strategy for Breast Cancer
Department of Medicine Clinical Genetics and Breast Cancer Medicine Services Memorial Sloan-Kettering Cancer Center New York, New York | January 26, 2010 ABSTRACT: As knowledge increases about the processes underlying cancer, it is becoming feasible to design...
|
|
|
4 medical officers for Anaesthesia Department of Poly Clinic approved
The Health Ministry has approved the appointment of four experienced medical officers in Anaesthesia Department of Federal Government Services Hospital.4 medical officers for Anaesthesia Department of Poly Clinic approved.
|
|
|
Biotech Stock Alert for Hemispherx Biopharma Inc. Issued by InvestorSoup
DALLAS, Jan.25, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Hemispherx Biopharma Inc. (AMEX:HEB - News). The report includes financial, comparative and investment analyses, and pertinent industry information you...
|
|
|
Biotech Stock Alert for Hemispherx Biopharma Inc. Issued by InvestorSoup
(GlobeNewswire via COMTEX) ----InvestorSoup.com announces an investment report featuring Hemispherx Biopharma Inc.(AMEX:HEB). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an...
|
|
|
Biotech Stock Alert for Hemispherx Biopharma Inc. Issued by InvestorSoup
(GlobeNewswire via COMTEX) ----InvestorSoup.com announces an investment report featuring Hemispherx Biopharma Inc.(AMEX:HEB). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an...
|
|
|
Biotech Stock Alert for Hemispherx Biopharma Inc. Issued by InvestorSoup
DALLAS, Jan.25, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Hemispherx Biopharma Inc. (AMEX:HEB). The report includes financial, comparative and investment analyses, and pertinent industry information you need to...
|
|
|
Biotech Stock Alert for Hemispherx Biopharma Inc. Issued by Inves...
Company: Hemispherx BioPharma, Inc.(HEB) InvestorSoup.com announces an investment report featuring Hemispherx Biopharma Inc. (AMEX:HEB). The report includes financial, comparative and investment analyses, and pertinent industry information you need to...
|
|
|
Biotech Stock Alert for Hemispherx Biopharma Inc. Issued by
DALLAS, Jan.25, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Hemispherx Biopharma Inc. (AMEX:HEB). The report includes financial, comparative and investment analyses, and pertinent industry information you need to...
|
|
|
Biotech Stock Alert for Hemispherx Biopharma Inc. Issued by InvestorSoup
DALLAS, Jan.25, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Hemispherx Biopharma Inc. (AMEX: HEB). The report includes financial, comparative and investment analyses, and pertinent industry information you need to...
|
|
|
Microassay for Glucose-Induced Preproinsulin mRNA Expression to Assess Islet Functional Potency for Islet Transplantation
Background.The capacity for insulin synthesis in islets is important for islet transplantation to succeed. We developed a microassay that evaluates the potency of human islets by measuring changes in glucose-induced human insulin gene (INS) expression...
|
|
|
Poly-Pacific Announces Appointment of Philip Kempisty to Board of Directors and Proposed Share Consolidation
Poly-Pacific International Inc.('Poly-Pacific' or the 'Company') (TSX VENTURE: PMB)(OTCBB: PLYPF)(BERLIN: A0LGDN)(FRANKFURT: POZ) is pleased to announce the appointment of Mr. Philip C. Kempisty to the Board of Directors. Kempisty is a Certified...
|
|
|
Poly-Pacific Announces Appointment of Philip Kempisty to Board of Directors and Proposed Share Consolidation
Poly-Pacific International Inc.("Poly-Pacific" or the "Company") (TSX VENTURE:PMB)(OTCBB:PLYPF)(BERLIN:A0LGDN)(FRANKFURT:POZ) is pleased to announce the appointment of Mr. Philip C. Kempisty to the Board of Directors. Kempisty is a...
|
